Table 1.

Characteristics of 60 basal cell nevus syndrome patients enrolled in clinical trial

A. Baseline characteristics of study participants (mean ± SD)
Placebo (n = 27)Celecoxib (n = 33)
Age42 ± 1247 ± 12
Number of BCC tumors >4 mm 24 ± 2332 ± 60
Body mass index (kg/m2)31 ± 1.330 ± 1.1
% Male48%58%
% Caucasian96%100%
% With ≥15 BCCs at baseline41%39%
% Seen at California site59%55%
B. Reason for patient termination
PlaceboCelecoxibTotal
Early discontinuation 4 (14%)5 (15%)9 (15%)
Lost to follow-up1 (3.7%)0 (0%)1 (1.7%)
Protocol noncompliance6 (22%)4 (12%)10 (17%)
Adverse events1 (3.7%)3 (9.1%)4 (6.7%)
Subject withdrew1 (3.7%)2 (6.1%)3 (5.0%)
Other3 (11%)4 (12%)7 (12%)